Cargando…
Clinical Trial Subgroup Analyses to Investigate Clinical and Immunological Outcomes of Convalescent Plasma Therapy in Severe COVID-19
OBJECTIVE: To assess the clinical and immunological benefits of passive immunization using convalescent plasma therapy (CPT). MATERIALS AND METHODS: A series of subclass analyses were performed on the previously published outcome data and accompanying clinical metadata from a completed randomized co...
Autores principales: | Raychaudhuri, Deblina, Bandopadhyay, Purbita, D’Rozario, Ranit, Sarif, Jafar, Ray, Yogiraj, Paul, Shekhar Ranjan, Singh, Praveen, Chaudhuri, Kausik, Bhaduri, Ritwik, Pandey, Rajesh, Bhattacharya, Prasun, Sengupta, Shantanu, Chatterjee, Shilpak, Ganguly, Dipyaman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472644/ https://www.ncbi.nlm.nih.gov/pubmed/36117954 http://dx.doi.org/10.1016/j.mayocpiqo.2022.09.001 |
Ejemplares similares
-
Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19
por: D’Rozario, Ranit, et al.
Publicado: (2023) -
Association of gut microbial dysbiosis with disease severity, response to therapy and disease outcomes in Indian patients with COVID-19
por: Talukdar, Daizee, et al.
Publicado: (2023) -
Suppressed transcript diversity and immune response in COVID-19 ICU patients: a longitudinal study
por: Mehta, Priyanka, et al.
Publicado: (2023) -
Plasma Gradient of Soluble Urokinase-Type Plasminogen Activator Receptor Is Linked to Pathogenic Plasma Proteome and Immune Transcriptome and Stratifies Outcomes in Severe COVID-19
por: Sarif, Jafar, et al.
Publicado: (2021) -
A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
por: Ray, Yogiraj, et al.
Publicado: (2022)